New York, New York (PRWEB) June 16, 2014
GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) filed in the wake of the 2012 GranuFlo and NaturaLyte recall continue to mount in the federal multidistrict litigation now underway in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. According to an updated Docket Report issued by the U.S. Judicial Panel on Multidistrict Litigation on June 16, 2014, at least 1,863 claims are now pending in the proceeding. Court documents indicate that all of the lawsuits filed in the federal GranuFlo recall litigation were brought on behalf of dialysis patients who allegedly suffered heart attacks, strokes, sudden cardiac death or other catastrophic cardiovascular events due to the administration of GranuFlo or NaturaLyte dialysis concentrates. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“Our Firm is representing a number of clients who have filed GranuFlo lawsuits in this proceeding, and we continue to receive inquiries from individuals who were allegedly harmed by products included in the GranuFlo and NaturaLyte recall. It is not surprising that the number of claims in the litigation has surpassed 1,800,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering free GranuFlo lawsuit reviews to dialysis patients who allegedly suffered serious heart injuries related to the GranuFlo and NaturaLyte recall.
According to court documents, all of the GranuFlo and NaturaLyte lawsuits pending in the District of Massachusetts allege that Fresenius Medical failed to provide adequate warnings or instructions for use for GranuFlo or NaturaLyte prior to their 2012 recall, increasing the risk that dialysis patients would suffer serious cardiovascular problems during or shortly after a dialysis treatment. The lawsuits also claim that the company continued to aggressively market GranuFlo and NaturaLyte even once it became aware of those risks.
Both GranuFlo and NaturaLyte were named in a Class I recall in 2012, after hundreds of people undergoing dialysis treatments at Fresenius clinics suffered life-threatening and sometimes deadly episodes of cardiac arrest. According to a report from The New York Times, many doctors were not aware that because of a unique formulation, GranuFlo and NaturaLyte had to be dosed differently than other dialysis concentrates. If this difference was not accounted for, a patient could experience a dangerous elevation of bicarbonate in the blood known as metabolic alkalosis. This condition makes it more likely that a dialysis patient will experience deadly heart events during or shortly after their dialysis treatment.*
Dialysis patients who suffered heart attacks, strokes or other life-threatening cardiac events within 72 hours of a dialysis treatment that involved the administration of GranuFlo and NaturaLyte may be entitled to compensation. To learn more about filing a GranuFlo lawsuit, please visit Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.
*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP